JP2017505284A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505284A5 JP2017505284A5 JP2016531028A JP2016531028A JP2017505284A5 JP 2017505284 A5 JP2017505284 A5 JP 2017505284A5 JP 2016531028 A JP2016531028 A JP 2016531028A JP 2016531028 A JP2016531028 A JP 2016531028A JP 2017505284 A5 JP2017505284 A5 JP 2017505284A5
- Authority
- JP
- Japan
- Prior art keywords
- ethoxy
- amino
- acetyl
- hpyy
- carboxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 119
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 73
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 67
- -1 PYY compound Chemical class 0.000 claims 40
- 101100289894 Caenorhabditis elegans lys-7 gene Proteins 0.000 claims 30
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 23
- 208000008589 Obesity Diseases 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 6
- 125000006308 propyl amino group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010006550 Bulimia nervosa Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 206010012655 Diabetic complications Diseases 0.000 claims 2
- 206010061818 Disease progression Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 239000000164 antipsychotic agent Substances 0.000 claims 2
- 229940005529 antipsychotics Drugs 0.000 claims 2
- 235000019789 appetite Nutrition 0.000 claims 2
- 230000036528 appetite Effects 0.000 claims 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 230000003915 cell function Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000005750 disease progression Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- 230000030135 gastric motility Effects 0.000 claims 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000036186 satiety Effects 0.000 claims 2
- 235000019627 satiety Nutrition 0.000 claims 2
- 201000002859 sleep apnea Diseases 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims 1
- 108010019598 Liraglutide Proteins 0.000 claims 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229960002701 liraglutide Drugs 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229950011186 semaglutide Drugs 0.000 claims 1
- 108010060325 semaglutide Proteins 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- 0 CS(CCCCCCCCCCCCCCCC(N[C@@](CCC(NCCOCCOCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@](C(*)=O)N*)=O)=O)=O)=O)C(O)=O)=O)(O)(O)O Chemical compound CS(CCCCCCCCCCCCCCCC(N[C@@](CCC(NCCOCCOCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@](C(*)=O)N*)=O)=O)=O)=O)C(O)=O)=O)(O)(O)O 0.000 description 2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13193082.8 | 2013-11-15 | ||
| EP13193082 | 2013-11-15 | ||
| US201361906020P | 2013-11-19 | 2013-11-19 | |
| US61/906,020 | 2013-11-19 | ||
| EP14176725 | 2014-07-11 | ||
| EP14176725.1 | 2014-07-11 | ||
| PCT/EP2014/074476 WO2015071355A1 (en) | 2013-11-15 | 2014-11-13 | Selective pyy compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019117619A Division JP2019189632A (ja) | 2013-11-15 | 2019-06-25 | 選択的なｐｙｙ化合物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017505284A JP2017505284A (ja) | 2017-02-16 |
| JP2017505284A5 true JP2017505284A5 (OSRAM) | 2017-12-21 |
| JP6602760B2 JP6602760B2 (ja) | 2019-11-06 |
Family
ID=53056816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016531028A Active JP6602760B2 (ja) | 2013-11-15 | 2014-11-13 | 選択的なｐｙｙ化合物及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9085637B2 (OSRAM) |
| EP (1) | EP3068421B1 (OSRAM) |
| JP (1) | JP6602760B2 (OSRAM) |
| KR (1) | KR20160075819A (OSRAM) |
| CN (1) | CN105722526B (OSRAM) |
| AU (1) | AU2014350197B2 (OSRAM) |
| BR (1) | BR112016010383A2 (OSRAM) |
| CA (1) | CA2929672A1 (OSRAM) |
| IL (1) | IL245045B (OSRAM) |
| MX (1) | MX369818B (OSRAM) |
| PL (1) | PL3068421T3 (OSRAM) |
| RS (1) | RS59026B1 (OSRAM) |
| SI (1) | SI3068421T1 (OSRAM) |
| TW (1) | TWI661835B (OSRAM) |
| WO (1) | WO2015071355A1 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
| US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
| AU2014261336B2 (en) | 2013-05-02 | 2019-02-28 | Novo Nordisk A/S | Oral dosing of GLP-1 compounds |
| CA2909045C (en) * | 2013-05-02 | 2022-12-06 | Glaxosmithkline Intellectual Property Development Limited | Therapeutic peptides |
| US10583172B2 (en) | 2013-11-15 | 2020-03-10 | Novo Nordisk A/S | HPYY(1-36) having a beta-homoarginine substitution at position 35 |
| US9085637B2 (en) | 2013-11-15 | 2015-07-21 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
| TWI694082B (zh) * | 2015-06-12 | 2020-05-21 | 丹麥商諾佛 儂迪克股份有限公司 | 選擇性ｐｙｙ化合物及其用途 |
| MX2018012700A (es) * | 2016-04-28 | 2019-01-30 | Novo Nordisk As | Semaglutida en afecciones cardiovasculares. |
| MA46780A (fr) | 2016-11-07 | 2019-09-11 | Novo Nordisk As | Esters à dchbs actif de composés peg et leur utilisation |
| CN109248323B (zh) * | 2017-07-14 | 2023-09-08 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| JP2020527159A (ja) | 2017-07-19 | 2020-09-03 | ノヴォ ノルディスク アー／エス | Ｅｇｆ（ａ）類似体、その製造、製剤および使用 |
| EP3474820B1 (en) | 2017-08-24 | 2024-02-07 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
| US20210171598A1 (en) | 2017-12-01 | 2021-06-10 | University Of Copenhagen | Peptide hormone with one or more o-glycans |
| MX2020007167A (es) * | 2018-01-09 | 2020-11-06 | Gila Therapeutics Inc | Composiciones y metodos para tratar enfermedades metabolicas. |
| BR112020014624A2 (pt) | 2018-02-02 | 2020-12-08 | Novo Nordisk A/S | Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante |
| GB2573145A (en) * | 2018-04-26 | 2019-10-30 | Univ Ulster | Peptides for metabolic disease |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| TW202535916A (zh) * | 2018-11-01 | 2025-09-16 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
| EP4009957B1 (en) * | 2019-08-07 | 2023-10-11 | Novo Nordisk A/S | Solid composition comprising a pyy compound and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| MX2022005661A (es) | 2019-11-11 | 2022-09-07 | Boehringer Ingelheim Int | Agonistas del receptor npy2. |
| WO2022029231A1 (en) | 2020-08-07 | 2022-02-10 | Boehringer Ingelheim International Gmbh | Soluble npy2 receptor agonists |
| JP2023551122A (ja) * | 2020-11-09 | 2023-12-07 | エンバーク バイオテック エーピーエス | 化合物およびタキキニン受容体介在性障害の治療におけるその使用 |
| JP2025526148A (ja) | 2022-08-18 | 2025-08-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 長時間作用型ｇｌｐ－１／グルカゴン受容体アゴニスト及びｎｐｙ２受容体アゴニストを含む組合せ治療 |
| WO2025128624A2 (en) * | 2023-12-12 | 2025-06-19 | Carmot Therapeutics, Inc. | Hybrid peptide compounds having a substituted tryptophan residue or a terminal substituent |
| WO2025128626A1 (en) * | 2023-12-12 | 2025-06-19 | Carmot Therapeutics, Inc. | Hybrid peptide compounds having a modified lysine residue |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL310897A1 (en) | 1993-03-29 | 1996-01-08 | Univ Cincinnati | Analogues of yy peptide and their application |
| US5574010A (en) | 1994-11-14 | 1996-11-12 | The Regents Of The University Of California | Treatment of pancreatic tumors with peptide YY and analogs thereof |
| CA2271788A1 (en) | 1996-11-13 | 1998-05-22 | University Of Cincinnati | Analogs of peptide yy and uses thereof |
| EP0908515A3 (en) | 1997-09-16 | 2000-04-26 | Smithkline Beecham Plc | Pancreatic polypeptide |
| US6046167A (en) | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
| CN1311773A (zh) | 1998-06-08 | 2001-09-05 | 先灵公司 | 神经肽y5受体拮抗剂 |
| US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| RU2275207C2 (ru) | 2000-12-14 | 2006-04-27 | Амилин Фармасьютикалз, Инк. | Способ снижения доступности питательного вещества, способ подавления аппетита |
| US6589938B2 (en) | 2001-06-29 | 2003-07-08 | National University Of Singapore | Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders |
| NZ532427A (en) | 2001-09-24 | 2008-07-31 | Imp Innovations Ltd | Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y) |
| US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
| EP2277527A3 (en) * | 2003-01-17 | 2011-08-31 | Ipsen Pharma | Peptide YY analogs |
| US7572581B2 (en) | 2003-06-30 | 2009-08-11 | Roche Molecular Systems, Inc. | 2′-terminator nucleotide-related methods and systems |
| CN100444898C (zh) | 2003-09-19 | 2008-12-24 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
| TW200526254A (en) | 2003-09-19 | 2005-08-16 | Novo Nordisk As | Novel GLP-1 derivatives |
| EP1667724A2 (en) | 2003-09-19 | 2006-06-14 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| CN101665538A (zh) | 2003-12-18 | 2010-03-10 | 诺沃挪第克公司 | 与白蛋白样物质相连的新glp-1类似物 |
| EP2417980A1 (en) | 2004-02-11 | 2012-02-15 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
| US8603969B2 (en) | 2004-02-11 | 2013-12-10 | Amylin Pharmaceuticals, Llc | Pancreatic polypeptide family motifs and polypeptides comprising the same |
| MXPA06010345A (es) | 2004-03-17 | 2007-06-19 | 7Tm Pharma As | Agonistas de receptor selectivo de y4 para intervenciones terapeuticas. |
| MXPA06010347A (es) | 2004-03-17 | 2007-06-19 | 7Tm Pharma As | Agonistas de receptor selectivo de y2 para intervenciones terapeuticas. |
| CN101361967A (zh) | 2004-03-17 | 2009-02-11 | 7Tm制药联合股份有限公司 | 用于治疗性干预的y2/y4选择性受体激动剂 |
| GB2427550B (en) | 2004-03-17 | 2007-05-30 | 7Tm Pharma As | Y2/Y4 selective receptor agonists for therapeutic interventions |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| MXPA06015049A (es) | 2004-07-08 | 2007-02-08 | Novo Nordisk As | Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol. |
| WO2006020207A2 (en) | 2004-07-19 | 2006-02-23 | University Of Cincinnati | Compounds for control of appetite |
| WO2006049681A2 (en) | 2004-08-30 | 2006-05-11 | Bayer Pharmaceuticals Corporation | Selective neuropeptide y2 receptor agonists |
| US7410949B2 (en) | 2005-01-18 | 2008-08-12 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
| GB0504857D0 (en) | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| CA2614619A1 (en) | 2005-07-11 | 2007-01-18 | Nastech Pharmaceutical Company Inc. | Formulations for enhanced mucosal delivery of pyy |
| WO2007009894A2 (en) | 2005-07-18 | 2007-01-25 | Novo Nordisk A/S | Peptides for use in the treatment of obesity |
| JP2009508885A (ja) | 2005-09-21 | 2009-03-05 | ７ティーエム ファーマ エイ／エス | 治療的介入のためのｙ４選択性レセプターアゴニスト |
| US7851590B2 (en) | 2005-09-21 | 2010-12-14 | 7Tm Pharma A/S | Y2 selective receptor agonists for therapeutic interventions |
| AU2006324076A1 (en) | 2005-12-07 | 2007-06-14 | F. Hoffmann-La Roche Ag | Neuropeptide-2 receptor-agonists |
| US20100029903A1 (en) | 2005-12-14 | 2010-02-04 | Novo Nordisk A/S | Polypeptide Protracting Tags |
| US20070197445A1 (en) | 2006-01-18 | 2007-08-23 | University Of Cincinnati | Compounds for control of appetite |
| EP2004238A2 (en) | 2006-03-21 | 2008-12-24 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
| GB0613196D0 (en) | 2006-07-03 | 2006-08-09 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| US20090099074A1 (en) | 2007-01-10 | 2009-04-16 | Conjuchem Biotechnologies Inc. | Modulating food intake |
| US20100016237A1 (en) | 2007-01-18 | 2010-01-21 | Novo Nordisk A/S | Novel Peptides for Use in the Treatment of Obesity |
| EP2101822A2 (en) | 2007-01-18 | 2009-09-23 | Novo Nordisk A/S | Use of peptides in combination with surgical intervention for the treatment of obesity |
| GB0708226D0 (en) | 2007-04-27 | 2007-06-06 | 7Tm Pharma As | Y-receptor agonists |
| US20100279930A1 (en) | 2007-07-09 | 2010-11-04 | Stephen Robert Bloom | Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour |
| WO2009030771A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| WO2009040019A2 (en) | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| EP2195034A2 (en) | 2007-09-27 | 2010-06-16 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of making and using same |
| MX2010011845A (es) | 2008-05-16 | 2010-11-22 | Novo Nordisk As | Agonistas del receptor y2 y/o y4 de larga accion. |
| US8299023B2 (en) * | 2008-09-17 | 2012-10-30 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists |
| GB0817067D0 (en) | 2008-09-18 | 2008-10-22 | 7Tm Pharma As | Intestinal treatment |
| CA2741921A1 (en) | 2008-11-05 | 2010-05-14 | F. Hoffmann-La Roche Ag | Neuropeptide-2-receptor (y-2r) agonists and uses thereof |
| CA2752608A1 (en) | 2009-02-20 | 2010-08-26 | Ipsen Pharma S.A.S. | Cytotoxic conjugates having neuropeptide y receptor binding compound |
| JP2013505221A (ja) * | 2009-09-18 | 2013-02-14 | ノヴォ ノルディスク アー／エス | 長時間作用性ｙ２受容体アゴニスト |
| WO2011045232A2 (en) | 2009-10-13 | 2011-04-21 | F. Hoffmann-La Roche Ag | Neuropeptide-2 receptor (y-2r) agonists |
| WO2011058165A1 (en) | 2009-11-13 | 2011-05-19 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| EP2560675A1 (en) | 2010-04-20 | 2013-02-27 | Novo Nordisk A/S | Long-acting gastrin derivatives |
| CA2797310C (en) * | 2010-05-05 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Glp-1 receptor agonist and dpp-4 inhibitor combination therapy |
| GB201101459D0 (en) | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
| US20150141336A1 (en) | 2012-05-29 | 2015-05-21 | Novo Nordisk A/S | Pancreatic Peptide Compounds and Use |
| CA2909045C (en) * | 2013-05-02 | 2022-12-06 | Glaxosmithkline Intellectual Property Development Limited | Therapeutic peptides |
| US9085637B2 (en) | 2013-11-15 | 2015-07-21 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
| US10583172B2 (en) | 2013-11-15 | 2020-03-10 | Novo Nordisk A/S | HPYY(1-36) having a beta-homoarginine substitution at position 35 |
| TWI694082B (zh) * | 2015-06-12 | 2020-05-21 | 丹麥商諾佛 儂迪克股份有限公司 | 選擇性ｐｙｙ化合物及其用途 |
-
2014
- 2014-11-13 US US14/540,474 patent/US9085637B2/en active Active
- 2014-11-13 WO PCT/EP2014/074476 patent/WO2015071355A1/en not_active Ceased
- 2014-11-13 JP JP2016531028A patent/JP6602760B2/ja active Active
- 2014-11-13 BR BR112016010383A patent/BR112016010383A2/pt not_active Application Discontinuation
- 2014-11-13 EP EP14798834.9A patent/EP3068421B1/en active Active
- 2014-11-13 MX MX2016006053A patent/MX369818B/es active IP Right Grant
- 2014-11-13 KR KR1020167015805A patent/KR20160075819A/ko not_active Withdrawn
- 2014-11-13 US US15/036,201 patent/US10246497B2/en active Active
- 2014-11-13 CN CN201480062213.5A patent/CN105722526B/zh active Active
- 2014-11-13 CA CA2929672A patent/CA2929672A1/en not_active Withdrawn
- 2014-11-13 PL PL14798834T patent/PL3068421T3/pl unknown
- 2014-11-13 TW TW103139321A patent/TWI661835B/zh not_active IP Right Cessation
- 2014-11-13 SI SI201431251T patent/SI3068421T1/sl unknown
- 2014-11-13 RS RS20190792A patent/RS59026B1/sr unknown
- 2014-11-13 AU AU2014350197A patent/AU2014350197B2/en not_active Ceased
-
2016
- 2016-04-11 IL IL245045A patent/IL245045B/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505284A5 (OSRAM) | ||
| JP2018522843A5 (OSRAM) | ||
| RU2017145348A (ru) | Селективные соединения пептида yy и их применения | |
| JP2017500289A5 (OSRAM) | ||
| JP6379300B2 (ja) | ＧＬＰ及び免疫グロブリンハイブリッドＦｃ融合ポリペプチド及びその用途 | |
| Cho et al. | K-cells and glucose-dependent insulinotropic polypeptide in health and disease | |
| RU2523552C2 (ru) | Лекарственное средство, включающее совместное применение или комбинацию ингибитора dpp-iv и другого лекарственного средства для лечения диабета | |
| UA126960C2 (uk) | Похідна глюкагону | |
| BRPI0606992A2 (pt) | análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis | |
| JP2012006970A5 (OSRAM) | ||
| JP2017519739A5 (OSRAM) | ||
| JP2011528333A5 (OSRAM) | ||
| JP2019530638A (ja) | シクロヒスチジン−プロリンを有効成分として含む細胞保護用組成物 | |
| WO2014206563A2 (en) | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases | |
| JP2011526482A5 (OSRAM) | ||
| RU2014119711A (ru) | Трициклические соединения, композиции, содержащие указанные соединения, и их применения | |
| JP2020536121A5 (OSRAM) | ||
| JP2015517458A5 (OSRAM) | ||
| RU2740913C2 (ru) | Лечение нарушений со стороны печени, желчных путей и поджелудочной железы | |
| JP2013511287A5 (OSRAM) | ||
| CN113456820B (zh) | 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途 | |
| JP2014500244A5 (OSRAM) | ||
| RU2012126101A (ru) | Полипептидный конъюгат | |
| JP2013532970A5 (OSRAM) | ||
| RU2016119121A (ru) | Селективные соединения пептида yy и их применения |